Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Immunotherapy Toxicity.

Mantia CM, Buchbinder EI.

Hematol Oncol Clin North Am. 2019 Apr;33(2):275-290. doi: 10.1016/j.hoc.2018.12.008. Epub 2019 Jan 28. Review.

PMID:
30833000
2.

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.

Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, Miletello GP, Fishman MN, Gonzalez R, Clark JI, Richart JM, Lao CD, Tykodi SS, Silk AW, McDermott DF.

J Immunother Cancer. 2019 Feb 18;7(1):49. doi: 10.1186/s40425-019-0522-3.

3.

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.

Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, Ashenberg O, Ott PA, Buchbinder EI, Haq R, Hodi FS, Boland GM, Sullivan RJ, Frederick DT, Miao B, Moll T, Flaherty KT, Herlyn M, Jenkins RW, Thummalapalli R, Kowalczyk MS, CaƱadas I, Schilling B, Cartwright ANR, Luoma AM, Malu S, Hwu P, Bernatchez C, Forget MA, Barbie DA, Shalek AK, Tirosh I, Sorger PK, Wucherpfennig K, Van Allen EM, Schadendorf D, Johnson BE, Rotem A, Rozenblatt-Rosen O, Garraway LA, Yoon CH, Izar B, Regev A.

Cell. 2018 Nov 1;175(4):984-997.e24. doi: 10.1016/j.cell.2018.09.006.

PMID:
30388455
4.

Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients.

Tan SY, Najita J, Li X, Strazzulla LC, Dunbar H, Lee MY, Seery VJ, Buchbinder EI, Tawa NE, McDermott DF, Lee SJ, Atkins MB, Kim CC.

Melanoma Res. 2019 Feb;29(1):70-76. doi: 10.1097/CMR.0000000000000483.

PMID:
30169431
5.

Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma.

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ.

Nature. 2018 Mar 14;555(7696):402. doi: 10.1038/nature25145.

6.

Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.

Lee H, Hodi FS, Giobbie-Hurder A, Ott PA, Buchbinder EI, Haq R, Tolaney S, Barroso-Sousa R, Zhang K, Donahue H, Davis M, Gargano ME, Kelley KM, Carroll RS, Kaiser UB, Min L.

Cancer Immunol Res. 2017 Dec;5(12):1133-1140. doi: 10.1158/2326-6066.CIR-17-0208. Epub 2017 Oct 27.

7.

Biomarkers in Melanoma: Lessons from Translational Medicine.

Buchbinder EI, Flaherty KT.

Trends Cancer. 2016 Jun;2(6):305-312. doi: 10.1016/j.trecan.2016.05.003. Epub 2016 Jun 2. Review.

PMID:
28741528
8.

An immunogenic personal neoantigen vaccine for patients with melanoma.

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ.

Nature. 2017 Jul 13;547(7662):217-221. doi: 10.1038/nature22991. Epub 2017 Jul 5. Erratum in: Nature. 2018 Mar 14;555(7696):402.

9.

Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.

Nishino M, Giobbie-Hurder A, Manos MP, Bailey N, Buchbinder EI, Ott PA, Ramaiya NH, Hodi FS.

Clin Cancer Res. 2017 Aug 15;23(16):4671-4679. doi: 10.1158/1078-0432.CCR-17-0114. Epub 2017 Jun 7.

10.

Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.

Cagney DN, Alexander BM, Hodi FS, Buchbinder EI, Ott PA, Aizer AA.

J Neurooncol. 2017 May;133(1):221. doi: 10.1007/s11060-017-2485-x. No abstract available.

PMID:
28527005
11.

The Phoenix Rises: The Rebirth of Cancer Immunotherapy.

Blasutig IM, Farkona S, Buchbinder EI, Luke JJ, Sharma P, Sznol M.

Clin Chem. 2017 Jul;63(7):1190-1195. doi: 10.1373/clinchem.2016.267849. Epub 2017 May 17. No abstract available.

12.

Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.

Wang DY, Eroglu Z, Ozgun A, Leger PD, Zhao S, Ye F, Luke JJ, Joseph RW, Haq R, Ott PA, Hodi FS, Sosman JA, Johnson DB, Buchbinder EI.

Cancer Immunol Res. 2017 May;5(5):357-362. doi: 10.1158/2326-6066.CIR-16-0287. Epub 2017 Apr 10.

13.

A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.

Ibrahim N, Buchbinder EI, Granter SR, Rodig SJ, Giobbie-Hurder A, Becerra C, Tsiaras A, Gjini E, Fisher DE, Hodi FS.

Cancer Med. 2016 Nov;5(11):3041-3050. doi: 10.1002/cam4.862. Epub 2016 Oct 17.

14.

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.

Buchbinder EI, Gunturi A, Perritt J, Dutcher J, Aung S, Kaufman HL, Ernstoff MS, Miletello GP, Curti BD, Daniels GA, Patel SP, Kirkwood JM, Hallmeyer S, Clark JI, Gonzalez R, Richart JM, Lutzky J, Morse MA, Sullivan RJ, McDermott DF.

J Immunother Cancer. 2016 Sep 20;4:52. doi: 10.1186/s40425-016-0155-8. eCollection 2016.

15.

Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.

Cagney DN, Alexander BM, Hodi FS, Buchbinder EI, Ott PA, Aizer AA.

J Neurooncol. 2016 Sep;129(3):389-393. doi: 10.1007/s11060-016-2196-8. Epub 2016 Jul 11. Erratum in: J Neurooncol. 2017 May 19;:.

PMID:
27401151
16.

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.

Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder EI, Berghorn E, Ruisi M, Kong G, Jiang J, Horak C, Hodi FS.

Lancet Oncol. 2016 Jul;17(7):943-955. doi: 10.1016/S1470-2045(16)30126-7. Epub 2016 Jun 4. Erratum in: Lancet Oncol. 2016 Jul;17 (7):e270.

17.

Melanoma in 2015: Immune-checkpoint blockade - durable cancer control.

Buchbinder EI, Hodi FS.

Nat Rev Clin Oncol. 2016 Feb;13(2):77-8. doi: 10.1038/nrclinonc.2015.237. Epub 2016 Jan 20. No abstract available.

PMID:
26787285
18.

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI.

JAMA Oncol. 2016 Feb;2(2):234-40. doi: 10.1001/jamaoncol.2015.4368.

PMID:
26633184
19.

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.

Buchbinder EI, Desai A.

Am J Clin Oncol. 2016 Feb;39(1):98-106. doi: 10.1097/COC.0000000000000239. Review.

20.
21.

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.

Buchbinder EI, Sosman JA, Lawrence DP, McDermott DF, Ramaiya NH, Van den Abbeele AD, Linette GP, Giobbie-Hurder A, Hodi FS.

Cancer. 2015 Nov 15;121(22):4007-15. doi: 10.1002/cncr.29622. Epub 2015 Aug 11.

22.

Melanoma arising in a nevus of Ito: novel genetic mutations and a review of the literature on cutaneous malignant transformation of dermal melanocytosis.

Tse JY, Walls BE, Pomerantz H, Yoon CH, Buchbinder EI, Werchniak AE, Dong F, Lian CG, Granter SR.

J Cutan Pathol. 2016 Jan;43(1):57-63. doi: 10.1111/cup.12568. Epub 2015 Sep 21. Review.

PMID:
26260725
23.

Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.

Buchbinder EI, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):755-63. doi: 10.1016/j.clinthera.2015.02.003. Epub 2015 Mar 6. Review.

PMID:
25746738
24.

Interferon, interleukin-2, and other cytokines.

Buchbinder EI, McDermott DF.

Hematol Oncol Clin North Am. 2014 Jun;28(3):571-83. doi: 10.1016/j.hoc.2014.02.001. Epub 2014 Apr 3. Review.

PMID:
24880948
25.

Non-Gaussianities in New Ekpyrotic Cosmology.

Buchbinder EI, Khoury J, Ovrut BA.

Phys Rev Lett. 2008 May 2;100(17):171302. Epub 2008 May 2.

PMID:
18518270

Supplemental Content

Loading ...
Support Center